|1.||McMurray, John J V: 13 articles (10/2015 - 10/2012)|
|2.||Solomon, Scott D: 12 articles (10/2015 - 10/2012)|
|3.||Packer, Milton: 12 articles (10/2015 - 08/2002)|
|4.||Debiec, Hanna: 11 articles (05/2015 - 06/2002)|
|5.||Hersh, Louis B: 10 articles (05/2015 - 02/2002)|
|6.||Nanus, David M: 10 articles (05/2013 - 01/2004)|
|7.||Nanus, D M: 10 articles (01/2008 - 05/2000)|
|8.||Shen, R: 10 articles (01/2008 - 05/2000)|
|9.||Ronco, Pierre: 9 articles (05/2015 - 10/2004)|
|10.||Zile, Michael R: 8 articles (10/2015 - 09/2013)|
06/01/2000 - "Neutral endopeptidase 24.11 (NEP) inhibitors are known to have vascular, diuretic, and natriuretic effects that may be helpful in the treatment of congestive heart failure (CHF). "
08/01/2015 - "This study sought to examine the prognostic value of the soluble form of neprilysin (sNEP) in acute heart failure (AHF) and sNEP kinetics during hospital admission. "
02/01/1999 - "Recent studies have found that combined inhibition of ACE and neutral endopeptidase (NEP) may have a greater beneficial effect in the treatment of heart failure than inhibition of ACE alone. "
12/01/2015 - "Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?"
12/01/2015 - "The soluble form of neprilysin, which was recently identified in heart failure, is associated with cardiovascular outcomes. "
|2.||Hypertension (High Blood Pressure)
02/01/2011 - "Studies with genetically engineered mice showed that decreased expression of the transmembrane peptidase neprilysin (NEP) increases susceptibility to hypoxic pulmonary vascular remodeling and hypertension; in hypoxic wild-type mice, expression is decreased early in distal pulmonary arteries, where prominent vascular remodeling occurs. "
02/01/1990 - "These studies suggest that neutral endopeptidase inhibition may represent a new approach to treatment of some forms of hypertension."
07/01/1995 - "However, simultaneous neutral endopeptidase and ACE inhibition induces a synergistic effect, and might therefore represent an interesting new therapeutic approach to the treatment of essential hypertension."
06/01/1993 - "Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension."
04/01/1993 - "To determine the renal, endocrine and haemodynamic effects of an orally active inhibitor of the neutral endopeptidase EC 188.8.131.52 in essential hypertension. "
|3.||Pulmonary Hypertension (Ayerza Syndrome)
03/01/2009 - "These data suggest that neprilysin may be protective against chronic hypoxic pulmonary hypertension in the lung, at least in part by attenuating the growth of smooth muscle cells. "
03/01/2009 - "Early pharmacological studies showed a decrease in chronic hypoxic pulmonary hypertension with neprilysin inhibition. "
03/01/2009 - "We used a genetic approach to test the alternate hypothesis that neprilysin depletion increases chronic hypoxic pulmonary hypertension. "
10/01/1993 - "Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats."
03/01/2009 - "After chronic hypoxia, neprilysin-null mice exhibited exaggerated pulmonary hypertension and striking increases in muscularization of distal vessels. "
01/01/2002 - "This enkephalinase inhibitor has in fact been shown to be effective in reducing by almost half the stool output of 135 young children with acute diarrhea. "
01/01/1995 - "[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. "
08/17/2000 - "Racecadotril (acetorphan), an enkephalinase inhibitor with antisecretory and antidiarrheal actions, is an effective and safe treatment for acute diarrhea in adults and children. "
11/01/1992 - "[Action of acetorphan, an enkephalinase inhibitor, in acute diarrhea]."
04/01/2005 - "Together with anti-secretory agents, including inhibitors of enkephalinase and of the cystic fibrosis transmembrane conductance regulator, new treatment options for managing severe diarrhea in cholera could soon be available."
|5.||Alzheimer Disease (Alzheimer's Disease)
01/01/2014 - "Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease."
11/15/2014 - "The aim of this study is to evaluate the association between two neprilysin variants (rs989692 and rs3736187) and Alzheimer's disease (AD). "
01/01/2012 - "Previous studies have demonstrated the therapeutic potential of viral vector-mediated neprilysin (NEP) gene therapy in mouse models of Alzheimer's disease (AD). "
03/01/2005 - "Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons."
10/01/2015 - "Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice."
|1.||3- (1- biphenyl- 4- ylmethyl- 3- ethoxycarbonyl- 1- butylcarbamoyl)propionate- 3'- methyl- 2'- (pentanoyl(2'- (tetrazol- 5- ylate)biphenyl- 4'- ylmethyl)amino)butyrate
|3.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|4.||Neprilysin (Neutral Endopeptidase)
|5.||Amyloid (Amyloid Fibrils)
|9.||Angiotensin Receptors (Angiotensin II Receptor)
|4.||Cardiac Resynchronization Therapy